Bausch Health Cos (NYSE:BHC) Director Frank Lee Sells 24,456 Shares

Bausch Health Cos Inc. (NYSE:BHC) Director Frank Lee sold 24,456 shares of Bausch Health Cos stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total value of $132,796.08. Following the transaction, the director owned 49,339 shares in the company, valued at approximately $267,910.77. The trade was a 33.14% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bausch Health Cos Price Performance

Bausch Health Cos stock opened at $5.51 on Thursday. Bausch Health Cos Inc. has a 12-month low of $4.41 and a 12-month high of $8.69. The stock has a market cap of $2.06 billion, a P/E ratio of -1.70 and a beta of 0.42. The company has a 50-day moving average price of $5.42 and a 200 day moving average price of $6.13. The company has a current ratio of 1.32, a quick ratio of 0.97 and a debt-to-equity ratio of 54.68.

Bausch Health Cos (NYSE:BHC) last released its quarterly earnings data on Wednesday, April 29th. The company reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.81 by ($0.03). Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%.The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.37 billion. Sell-side analysts anticipate that Bausch Health Cos Inc. will post 4.08 earnings per share for the current year.

Key Bausch Health Cos News

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Bausch Health reported the results of its 2026 Annual Meeting, where shareholders elected all 10 director nominees and added Eiry W. Roberts, M.D. to the board, which may support governance and strategic execution. Bausch Health Announces 2026 Annual Meeting of Shareholder Results
• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $3.93 from $3.92, indicating slightly better near-term profit expectations.
• Neutral Sentiment: The company presented at the RBC Capital Markets Global Healthcare Conference and Barclays’ Leveraged Finance Conference, which kept investor attention on Bausch Health’s strategy and debt profile. Bausch Health Companies Inc. (BHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Director Frank D. Lee sold 24,456 shares under a pre-arranged Rule 10b5-1 plan; while routine, insider selling can still weigh on sentiment. SEC Form 4 filing
• Negative Sentiment: Zacks Research trimmed several forward EPS estimates, including Q2 2027, Q3 2027, Q4 2027, FY2027, Q1 2028 and FY2028, signaling softer long-term earnings expectations.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Caption Management LLC grew its stake in Bausch Health Cos by 101.1% in the 4th quarter. Caption Management LLC now owns 4,464 shares of the company’s stock worth $31,000 after acquiring an additional 405,789 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in Bausch Health Cos by 12,589.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock worth $34,000 after acquiring an additional 4,910 shares during the period. Northwestern Mutual Wealth Management Co. grew its stake in Bausch Health Cos by 6,661.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock worth $35,000 after acquiring an additional 5,329 shares during the period. Russell Investments Group Ltd. grew its stake in Bausch Health Cos by 65.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after acquiring an additional 3,106 shares during the period. Finally, Camelot Portfolios LLC purchased a new stake in Bausch Health Cos in the 4th quarter worth approximately $59,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on BHC shares. Barclays lowered their price objective on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 25th. Wall Street Zen cut shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Weiss Ratings cut shares of Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th. Royal Bank Of Canada cut their target price on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research report on Monday, April 27th. Finally, Raymond James Financial reaffirmed a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th. Four equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $8.00.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.